Evidence map›Paper›PMID 40295007›Full record

ArticleIn vivo (Athens, Greece)

Inhibitory Effect of Clopidogrel, a P2Y

Noriko Yoshikawa, Mingyu Xia, Kazuki Nakamura

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. EnhancedSkin health and disease · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Noriko YoshikawaDepartment of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
Mingyu XiaDepartment of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
Kazuki NakamuraDepartment of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan lfp51193@mukogawa-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe complex interactions between circulating platelets and tumor cells play important roles in tumor metastasis. Tumor cells can activate platelets by releasing mediators such as adenosine diphosphate (ADP). Treatments with anticoagulants have been shown to attenuate tumor metastasis. However, the role of ADP receptor P2Y MATERIALS AND

methodsIn this study, highly metastatic B16-BL6 mouse melanoma cells were injected into the tail vein of mice as a model of hematogenic tumor metastasis to investigate the effects of P2Y

resultsA high dose (25 mg/kg) of clopidogrel weakly but significantly inhibited lung metastasis and increased both the time to hemostasis and blood loss in the tail tip-excision mouse model.

conclusionAlthough it is necessary to consider increased bleeding as a side-effect, clopidogrel may be an effective antimetastatic drug.

Indexed as

ClopidogrelLung NeoplasmsMelanoma, ExperimentalPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12AnimalsCell Line, TumorDisease Models, AnimalMiceNeoplasm MetastasisClopidogrelPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12ADPclopidogrelmelanomametastasismouseP2Y12 receptorplatelet

Identifiers

PMID40295007
PMCPMC12041989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.